<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03625687</url>
  </required_header>
  <id_info>
    <org_study_id>2018P001697</org_study_id>
    <nct_id>NCT03625687</nct_id>
  </id_info>
  <brief_title>Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant</brief_title>
  <official_title>Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept, single center study for the donation of HCV-positive lungs to HCV
      negative recipient patients, with preemptive, interventional treatment with 12 weeks of
      commercially available DAA therapy to prevent HCV transmission upon transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this study is to determine if preoperative dosing and sustained administration of
      pan-genotypic DAA therapy after lungs transplantation prevents the transmission of hepatitis
      C virus (HCV) infection from an HCVpositive donor lung to an HCV naïve recipient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 5, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Undetectable blood HCV RNA level</measure>
    <time_frame>12 weeks post treatment</time_frame>
    <description>Negative HCV RNA by blood testing at 12 weeks after the last dose of treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety (based on number of adverse events and clinically significant lab values) of DAA therapy in patients undergoing lung transplantation</measure>
    <time_frame>12 weeks</time_frame>
    <description>Safety of commercially available DAA therapy in the lung transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating clinically significant laboratory results as compared to baseline/pretreatment values per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability (based on number of adverse events and clinically significant laboratory values)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Tolerability of commercially available DAA therapy in the lung transplant patient will be monitored by quantifying the number of treatment related adverse events per patient and evaluating clinically significant laboratory results</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>Respiratory Failure</condition>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 weeks of treatment with HCV Direct Acting Antiviral tablet (Mavyret or Epclusa)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clinically prescribed direct acting antiviral (Mavyret or Epclusa) HCV treatment for 12 weeks</intervention_name>
    <description>12 weeks of direct acting antiviral treatment based on clinical indication (either Mavyret or Epclusa)</description>
    <arm_group_label>Treatment with Direct Acting Antiviral for HCV</arm_group_label>
    <other_name>DAA treatment</other_name>
    <other_name>Mavyret</other_name>
    <other_name>Epclusa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Met MGH transplant center criteria, listed for lung transplant

          -  Able to sign informed consent

        Exclusion Criteria:

          -  Pregnant or nursing (lactating) women

          -  HIV positivity

          -  Any contra-indication to lung transplantation per center protocol

          -  For study patients in whom Epclusa® therapy is being considered, exclusion criteria
             includes patients on the following p-glycoprotein inducers or moderate to potent CYP
             inducers that cannot stop therapy: carbamazepine, phenytoin, phenobarbital,
             oxcarbazepine, rifabutin, rifampin, rifapentine, St. John's wort.

          -  For study patients in whom MavyretTM therapy is being considered, exclusion criteria
             includes patients on the following medications who cannot stop therapy: carbamazepine,
             rifampin, St. John's wort, and ethinyl estradiol-containing oral contraceptives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raymond T Chung, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raymond T Chung, MD</last_name>
    <phone>6177247562</phone>
    <email>RChung@partners.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jenna L Gustafson, MS</last_name>
    <phone>6177243836</phone>
    <email>jlgustafson@partners.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenna L Gustafson, MSc</last_name>
      <phone>617-724-3836</phone>
      <email>JLGustafson@partners.org</email>
    </contact>
    <investigator>
      <last_name>Raymond T Chung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>July 30, 2018</study_first_submitted>
  <study_first_submitted_qc>August 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Raymond T. Chung, MD</investigator_full_name>
    <investigator_title>Director of Hepatology</investigator_title>
  </responsible_party>
  <keyword>Lung disease</keyword>
  <keyword>Lung Transplant</keyword>
  <keyword>HCV</keyword>
  <keyword>Hepatitis C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Sofosbuvir-velpatasvir drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anticipate to share coded data with collaborators</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Anticipate data would be available to share within 6 months after the final patient completes the study.</ipd_time_frame>
    <ipd_access_criteria>Coded data would be shared with collaborators who have received IRB approval to use the data and have been approved by the PI for their collaboration.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

